SNHG9 was upregulated in NSCLC and associated with DDP-resistance and poor prognosis of NSCLC patients

Ruixue Wang; Changyu Chen; Weibiao Kang; Guangjun Meng

SNHG9 was upregulated in NSCLC and associated with DDP-resistance and poor prognosis of NSCLC patients

Am J Transl Res. 2020 Aug 15;12(8):4456-4466. eCollection 2020.

Authors

Ruixue Wang¹, Changyu Chen², Weibiao Kang³, Guangjun Meng¹

Affiliations

¹ Department of Emergency, The First Affiliated Hospital of Anhui Medical University Hefei 230031, Anhui Province, People's Republic of China.
² Department of Gastrointestinal Surgery, The First Affiliated Hospital of Nanchang University Nanchang 330006, Jiangxi Province, People's Republic of China.
³ Department of General Surgery, The First Affiliated Hospital of Anhui Medical University Hefei 230031, Anhui Province, People's Republic of China.

PMID: 32913519
PMCID: PMC7476120

Abstract

Lung cancer, a leading cause of cancer-related mortalities worldwide and non-small cell lung cancer (NSCLC) is the main subtype of lung cancer. As a first-line chemotherapeutic drug used for NSCLC, acquired resistance retarded the clinical application of cisplatin (DDP). We herein reported long non-coding RNA SNHG9 was over-expressed in NSCLC tissues and cell lines compared with normal lung tissues and cell line; Increased SNHG9 was also observed in DDP resistant NSCLC tissues and cell lines compared with their DDP sensitive counterparts. Elevated expression of SNHG9 was associated with lower overall survival (OS) rate in NSCLC patients. Besides, silence of SNHG9 suppressed DDP resistance of NSCLC cells. Furthermore, CAPRIN1 was positively regulated by SNHG9 and mediated the promoting role of SNHG9 in DDP resistance of NSCLC cells. SNHG9 could be used as a potential target for DDP resistant NSCLC therapy.

Keywords: CAPRIN1; NSCLC; SNHG9; cisplatin resistance.